整合药代动力学数据预测英夫利西单抗治疗溃疡性结肠炎内镜愈合的临床决策支持工具的开发与验证
基于ACT-1和ACT-2两项随机试验中484例溃疡性结肠炎患者数据,采用二室群体药代动力学模型计算基线英夫利西单抗清除率,建立并验证仅用基线变量预测第8周和第30周内镜愈合(Mayo内镜评分≤1)的多变量回归模型及临床决策支持工具。基线清除率、排便频率和直肠出血评分与第8周内镜愈合负相关,基线清除率、排便频率评分、白细胞计数和较低体重与第30周内镜愈合负相关。该工具可在线计算患者内镜愈合概率,外部验证模型预测价值中等(AUC 0.67)。
要点
- 基线英夫利西单抗清除率越高,第8周和第30周内镜愈合可能性越低。
- CDST评分≤9分识别第8周未愈合的敏感性为82%,≥16分识别愈合的特异性为87%。
- CDST评分≤17分识别第30周未愈合的敏感性为90%,>22分识别愈合的特异性为80%。
核心结论
- 利用英夫利西单抗清除率和基线患者及疾病指标开发的CDST可识别最可能实现内镜愈合的UC患者,有助于治疗决策和精准医学。
研究设计与样本
- 分析ACT-1和ACT-2随机试验中484例接受英夫利西单抗治疗的溃疡性结肠炎患者数据。
- 采用二室群体药代动力学模型计算基线英夫利西单抗清除率。
- 建立并验证仅使用基线变量预测第8周和第30周内镜愈合(Mayo内镜评分≤1)的两个多变量回归模型,并开发临床决策支持工具(CDST)和计算器。
主要发现
- 较高的基线英夫利西单抗清除率、排便频率和直肠出血评分与第8周内镜愈合负相关。
- 较高的基线英夫利西单抗清除率、排便频率评分、白细胞计数和较低体重与第30周内镜愈合负相关。
- 验证集中,CDST评分≤9分识别第8周未愈合的敏感性为82%(95% CI,76%-88%),≥16分识别第8周愈合的特异性为87%(95% CI,81%-94%)。
- 验证集中,CDST评分≤17分识别第30周未愈合的敏感性为90%(95% CI,85%-95%),>22分识别第30周愈合的特异性为80%(95% CI,73%-87%)。
- 外部验证模型预测价值中等,曲线下面积为0.67(95% CI,0.61-0.74)。
关键数值与推荐
- 内镜愈合定义为Mayo内镜评分≤1。
- 第8周:CDST评分≤9分识别未愈合(敏感性82%,95% CI 76%-88%),≥16分识别愈合(特异性87%,95% CI 81%-94%)。
- 第30周:CDST评分≤17分识别未愈合(敏感性90%,95% CI 85%-95%),>22分识别愈合(特异性80%,95% CI 73%-87%)。
- 患者第8周或第30周内镜愈合的个体概率可在www.premedibd.com在线计算。
临床怎么用
- 在启动英夫利西单抗治疗前,可使用CDST基于基线英夫利西单抗清除率、排便频率、直肠出血评分、白细胞计数和体重等变量评估第8周和第30周内镜愈合概率。
- 根据CDST评分分层识别可能未愈合或愈合的患者,辅助治疗决策和精准医学。
局限性
- 外部验证模型预测价值中等,AUC为0.67(95% CI,0.61-0.74)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Infliximab is an effective treatment for moderate to severe ulcerative colitis (UC). Little is known about patient-related factors that might be used to predict endoscopic healing with infliximab therapy. METHODS: We analyzed data from 484 patients included in the randomized trials of the effects of infliximab therapy for patients with UC (Active Ulcerative Colitis Trials [ACT]-1 and ACT-2). We used a 2-compartment population pharmacokinetic model to calculate baseline infliximab clearance. Two multivariable regression models were derived and validated for their ability to identify patients with endoscopic healing (Mayo endoscopic score, ≤1) at weeks 8 and 30, using only baseline variables. We developed a clinical decision support tool (CDST) and calculator to determine the probability of endoscopic healing in patients starting infliximab. RESULTS: Higher baseline infliximab clearance, stool frequency, and rectal bleeding scores were associated negatively with endoscopic healing at week 8. In the validation set, a CDST score of 9 points or fewer identified patients without endoscopic healing at week 8 with 82% sensitivity (95% CI, 76%-88%), whereas a CDST score of 16 points or more identified patients with endoscopic healing at week 8 with 87% specificity (95% CI, 81%-94%). Higher baseline infliximab clearance, stool frequency score, white blood cell count, and lower body weight were associated negatively with endoscopic healing at week 30. In the validation set, CDST scores of 17 points or fewer identified patients without endoscopic healing at week 30 with 90% sensitivity (95% CI, 85%-95%), whereas scores greater than 22 points identified patients with endoscopic healing at week 30 with 80% specificity (95% CI, 73%-87%). External validation models had a modest predictive value, with an area under of the curve of 0.67 (95% CI, 0.61-0.74). Patient-level probabilities of endoscopic healing at weeks 8 or 30 can be calculated online (www.premedibd.com). CONCLUSIONS: Using data from 2 clinical trials of patients receiving infliximab therapy for UC, we developed and validated the CDST, which uses data on infliximab clearance and baseline patient and disease measures to identify patients most likely to have endoscopic healing. This tool will facilitate therapy decision making and precision medicine.
引用
- Vande Casteele N, Jairath V, Jeyarajah J, et al. Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab. Clin Gastroenterol Hepatol. 2020. PMID: 32376505. doi:10.1016/j.cgh.2020.04.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。